DalsnaFinance

Dupilumab Improves Outcomes for EoG in Phase 2 Clinical Trial

Markets PR Newswire By PR Newswire 29 Jun 2026 14:23 1 min read
Dupilumab Improves Outcomes for EoG in Phase 2 Clinical Trial

11-center CEGIR network study led by Cincinnati Children's advances our understanding of eosinophilic gastritis – a rare inflammatory food allergic disease of the stomach – and potentially opens promising avenues for development of new therapeutic approaches. CINCINNATI, June 29, 2026...

11-center CEGIR network study led by Cincinnati Children's advances our understanding of eosinophilic gastritis – a rare inflammatory food allergic disease of the stomach – and potentially opens promising avenues for development of new therapeutic approaches. CINCINNATI, June 29, 2026...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.